结直肠癌是美国第二主要的癌症相关死因，每年全球约有100万人死于该病。肝脏是结直肠癌转移最常见的部位，显著地推动了发病率和死亡率。近年来，在结直肠癌肝转移患者管理方面取得了显著进展，但早期发现、防止进展和复发，以及开发更有效的治疗方法仍面临着重大挑战。2017年，我们团队举办了一次多学科领域的先进科技综述会议，就结直肠癌肝转移领域的快速发展中的临床和科学进展进行讨论，包括新颖的早期检测和预后液态生物标志物、高风险人群的识别、肿瘤免疫治疗的进展以及不同区域和全身的治疗策略。自那时起，科学发现已转化为解决当前管理挑战的治疗创新，这些创新正在重塑治疗范例并推动进一步的科学发现。在此，我们提出了关于结直肠癌肝转移管理中科学和临床进展以及未来方向的最新讨论，包括移植T细胞治疗、新型基于血液的生物标志物和肿瘤微生物组的作用。此外，我们还提供了一份全面的概述，详细介绍了在结直肠癌肝转移患者管理中使用的现代多学科临床方法的作用，包括对下一代测序确定的特定分子肿瘤配置文件的考虑，以及这些创新治疗对生活质量的影响。版权所有 © 2023 作者。由 Elsevier Inc. 出版。保留所有权利。

Colorectal cancer is the 2nd leading cause of cancer-related deaths in the United States and accounts for an estimated 1 million deaths annually worldwide. The liver is the most common site of metastatic spread from colorectal cancer, significantly driving both morbidity and mortality. While remarkable advances have been made in recent years in the management for patients with colorectal cancer liver metastases, significant challenges remain in early detection, prevention of progression and recurrence, and in the development of more effective therapeutics. In 2017, our group held a multidisciplinary state-of-the science symposium, in order to discuss the rapidly evolving clinical and scientific advances in the field of colorectal liver metastases, including novel early detection and prognostic liquid biomarkers, identification of high-risk cohorts, advances in tumor-immune therapy, and different regional and systemic therapeutic strategies. Since that time, there has been scientific discoveries translating into therapeutic innovations addressing the current management challenges. These innovations are currently reshaping the treatment paradigms and spurring further scientific discovery. Herein, we present an updated discussion of both the scientific and clinical advances and future directions in the management of colorectal liver metastases, including adoptive T-cell therapies, novel blood-based biomarkers, and the role of the tumor microbiome. Additionally, we provide a comprehensive overview detailing the role of modern multidisciplinary clinical approaches used in the management of patients with colorectal liver metastases, including considerations towards specific molecular tumor profiles identified on next generation sequencing, as well as quality of life implications for these innovative treatments.Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.